Cosmo Bio Company,Limited (TYO:3386)
Japan · Delayed Price · Currency is JPY 1,287.00
+10.00 (0.78%)
Apr 3, 2026, 1:05 PM JST
Cosmo Bio Company,Limited Revenue
In the year 2025, Cosmo Bio Company,Limited had annual revenue of 10.77B JPY with 7.26% growth. Cosmo Bio Company,Limited had revenue of 2.88B in the quarter ending December 31, 2025, with 9.63% growth.
Revenue
10.77B
Revenue Growth
+7.26%
P/S Ratio
0.68
Revenue / Employee
59.15M
Employees
182
Market Cap
7.30B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 10.77B | 729.00M | 7.26% |
| Dec 31, 2024 | 10.04B | 697.00M | 7.46% |
| Dec 31, 2023 | 9.34B | -213.00M | -2.23% |
| Dec 31, 2022 | 9.55B | 322.00M | 3.49% |
| Dec 31, 2021 | 9.23B | 1.14B | 14.08% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Takeda Pharmaceutical Company | 4.46T |
| Otsuka Holdings | 2.47T |
| Chugai Pharmaceutical | 1.26T |
| HOYA Corporation | 915.21B |
| As Partners CO.,LTD. | 22.84B |
| J Frontier | 21.34B |
| Advantage Risk Management | 9.85B |
| PRISM BioLab Co.,LTD | 684.61M |